# STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

> **NCT06975293** · PHASE1,PHASE2 · RECRUITING · sponsor: **STORM Therapeutics LTD** · enrollment: 107 (estimated)

## Conditions studied

- Solid Tumor
- Sarcoma
- Leiomyosarcoma
- Dedifferentiated Liposarcoma

## Interventions

- **COMBINATION_PRODUCT:** STC-15 in combination with toripalimab
- **DRUG:** STC-15 monotherapy

## Key facts

- **NCT ID:** NCT06975293
- **Lead sponsor:** STORM Therapeutics LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2027-12-29
- **Final completion:** 2028-06-29
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975293, "STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06975293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*